Your browser doesn't support javascript.
loading
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent, Martin; Gan, Hui K; Lassman, Andrew B; Kumthekar, Priya; Merrell, Ryan; Butowski, Nicholas; Lwin, Zarnie; Mikkelsen, Tom; Nabors, Louis B; Papadopoulos, Kyriakos P; Penas-Prado, Marta; Simes, John; Wheeler, Helen; Walbert, Tobias; Scott, Andrew M; Gomez, Erica; Lee, Ho-Jin; Roberts-Rapp, Lisa; Xiong, Hao; Bain, Earle; Ansell, Peter J; Holen, Kyle D; Maag, David; Reardon, David A.
Afiliação
  • van den Bent M; Brain Tumor Center, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl.
  • Gan HK; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
  • Lassman AB; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • Kumthekar P; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
  • Merrell R; Northwestern University, Chicago, IL, USA.
  • Butowski N; NorthShore University Health System, Evanston, IL, USA.
  • Lwin Z; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
  • Mikkelsen T; Department of Medical Oncology, School of Medicine, University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Nabors LB; Henry Ford Health System, Detroit, MI, USA.
  • Papadopoulos KP; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Penas-Prado M; South Texas Accelerated Research Therapeutics (START), San Antonio, TX, USA.
  • Simes J; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wheeler H; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Walbert T; Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Scott AM; Henry Ford Health System, Detroit, MI, USA.
  • Gomez E; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
  • Lee HJ; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • Roberts-Rapp L; AbbVie Inc., North Chicago, IL, USA.
  • Xiong H; AbbVie Inc., North Chicago, IL, USA.
  • Bain E; AbbVie Inc., North Chicago, IL, USA.
  • Ansell PJ; AbbVie Inc., North Chicago, IL, USA.
  • Holen KD; AbbVie Inc., North Chicago, IL, USA.
  • Maag D; AbbVie Inc., North Chicago, IL, USA.
  • Reardon DA; AbbVie Inc., North Chicago, IL, USA.
Cancer Chemother Pharmacol ; 80(6): 1209-1217, 2017 Dec.
Article em En | MEDLINE | ID: mdl-29075855
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glioblastoma / Imunoconjugados / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glioblastoma / Imunoconjugados / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Holanda